Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.7K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

The Lancet. Oncology·2026
Same author

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same author

Delta-like Ligand 3-Directed <sup>225</sup>Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Computed Quantitative Planar Imaging for Targeted Alpha Therapy: Model-Based Sparse Reconstruction Validated With a Novel <sup>225</sup>Ac Epoxy Phantom.

IEEE transactions on medical imaging·2026
Same author

Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management.

Insights into imaging·2026
Same author

Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers.

Proceedings of the National Academy of Sciences of the United States of America·2026

Related Experiment Video

Updated: Feb 23, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

19.0K

Somatostatin Receptor 2-Targeting Compounds.

Daan A Smit Duijzentkunst1, Dik J Kwekkeboom2, Lisa Bodei3

  • 1Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands; and d.smitduijzentkunst@erasmusmc.nl.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|September 3, 2017
PubMed
Summary
This summary is machine-generated.

Radiolabeled somatostatin analogs offer advanced molecular imaging and treatment for neuroendocrine tumors (NETs). Peptide receptor radionuclide therapy (PRRT) shows high disease control rates and improved survival in NET patients.

Keywords:
neuroendocrine tumorspeptide receptor radionuclide therapysomatostatin receptortheranostics

More Related Videos

A Strategy to Identify Compounds that Affect Cell Growth and Survival in Cultured Mammalian Cells at Low-to-Moderate Throughput
12:22

A Strategy to Identify Compounds that Affect Cell Growth and Survival in Cultured Mammalian Cells at Low-to-Moderate Throughput

Published on: September 22, 2019

9.0K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

Related Experiment Videos

Last Updated: Feb 23, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

19.0K
A Strategy to Identify Compounds that Affect Cell Growth and Survival in Cultured Mammalian Cells at Low-to-Moderate Throughput
12:22

A Strategy to Identify Compounds that Affect Cell Growth and Survival in Cultured Mammalian Cells at Low-to-Moderate Throughput

Published on: September 22, 2019

9.0K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Neuroendocrine tumors (NETs) diagnosis and staging have been transformed by molecular imaging using radiolabeled somatostatin analogs.
  • Whole-body scintigraphy with 111In-pentetreotide is a key diagnostic tool for NETs.
  • Positron-emitting radionuclide imaging achieves over 90% diagnostic accuracy.

Purpose of the Study:

  • To review the role of radiolabeled somatostatin analogs in the theranostic management of neuroendocrine tumors.
  • To highlight the efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) for NETs.
  • To discuss future advancements in PRRT.

Main Methods:

  • Review of diagnostic imaging techniques including 111In-pentetreotide scintigraphy and positron-emitting radionuclide imaging.
  • Evaluation of Peptide Receptor Radionuclide Therapy (PRRT) as a treatment modality for advanced NETs.
  • Analysis of clinical trial data comparing PRRT with other treatment strategies.

Main Results:

  • PRRT demonstrates high disease control rates (up to 95%) with low toxicity in patients with advanced NETs.
  • A randomized trial showed PRRT reduced disease progression and death by 79% compared to standard octreotide treatment for midgut NETs.
  • Diagnostic accuracy for NETs using positron-emitting radionuclides exceeds 90%.

Conclusions:

  • Radiolabeled somatostatin analogs are crucial for both diagnosis and therapy of NETs, establishing theranostic approaches.
  • PRRT is a well-established and effective treatment for advanced, well-differentiated NETs, significantly improving outcomes.
  • Future developments, including somatostatin receptor antagonists and alpha-emitting radionuclides, promise further enhancements in PRRT efficacy.